Lokelma

Drug overview for LOKELMA (sodium zirconium cyclosilicate):

Generic name: sodium zirconium cyclosilicate (SOE-dee-um zir-KOE-nee-um SYE-kloe-SIL-i-kate)
Drug class: Potassium-Removing Resins
Therapeutic class: Electrolyte Balance-Nutritional Products

Sodium zirconium cyclosilicate, a nonabsorbed cation-exchange crystalline compound, is used for the removal of excess potassium.

No enhanced Uses information available for this drug.

DRUG IMAGES

LOKELMA 10 GRAM POWDER PACKET
LOKELMA 5 GRAM POWDER PACKET

The following indications for LOKELMA (sodium zirconium cyclosilicate) have been approved by the FDA:

Indications:
Hyperkalemia

Professional Synonyms:
Hyperpotassemia

Dosing information for LOKELMA
DRUG LABEL	DOSING TYPE	DOSING INSTRUCTIONS
LOKELMA 5 GRAM POWDER PACKET	Maintenance	Adults take 1 packet (5 gram) mix in 45 mL water and drink immediately by oral route once daily rinse glass with water and drink for full dose
LOKELMA 10 GRAM POWDER PACKET	Maintenance	Adults take 1 packet (10 gram) mix in 45 mL water and drink immediately by oral route once daily rinse glass with water and drink for full dose

The following drug interaction information is available for LOKELMA (sodium zirconium cyclosilicate):

Contraindicated
Severe
Moderate

There are 0 contraindications.

There are 1 severe interactions. These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.

Drug Interaction	Drug Names
Potassium Supplements/Potassium Binders SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Patiromer, sodium polystyrene sulfonate and sodium zirconium cyclosilicate bind to potassium.(1-3) CLINICAL EFFECTS: Concurrent use of potassium supplements and patiromer, sodium polystyrene sulfonate or sodium zirconium cyclosilicate may decrease the effectiveness of both agents. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Patients should normally not receive potassium supplements and patiromer, sodium polystyrene sulfonate or sodium zirconium cyclosilicate concurrently.(1-3) Patiromer, sodium polystyrene sulfonate or sodium zirconium cyclosilicate are indicated for management of hyperkalemia. Consider discontinuing or holding potassium supplements in patients who develop hyperkalemia requiring treatment. DISCUSSION: Patiromer, sodium polystyrene sulfonate and sodium zirconium cyclosilicate are indicated for hyperkalemia. Consider discontinuing or holding potassium supplements in patients receiving sodium polystyrene sulfonate or sodium zirconium cyclosilicate.	DEXTROSE 5%-ELECTROLYTE #48, EFFER-K, K-PHOS NO.2, K-PHOS ORIGINAL, KCL-D5W-0.2% NACL, KCL-D5W-0.225% NACL, KCL-D5W-0.45% NACL, KCL-D5W-0.9% NACL, KLOR-CON, KLOR-CON 10, KLOR-CON 8, KLOR-CON M10, KLOR-CON M15, KLOR-CON M20, KLOR-CON-EF, POKONZA, POTASSIUM ACETATE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE IN D5LR, POTASSIUM CHLORIDE-0.45% NACL, POTASSIUM CHLORIDE-0.9% NACL, POTASSIUM CHLORIDE-DEXTROSE 5%, POTASSIUM CHLORIDE-WATER, POTASSIUM CL-LIDOCAINE-NS, POTASSIUM PHOSPHATE, POTASSIUM PHOSPHATE-0.9% NACL, POTASSIUM PHOSPHATES

Drug Interaction

Drug Names

Potassium Supplements/Potassium Binders

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Patiromer, sodium polystyrene sulfonate and sodium zirconium cyclosilicate bind to potassium.(1-3)

CLINICAL EFFECTS: Concurrent use of potassium supplements and patiromer, sodium polystyrene sulfonate or sodium zirconium cyclosilicate may decrease the effectiveness of both agents.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Patients should normally not receive potassium supplements and patiromer, sodium polystyrene sulfonate or sodium zirconium cyclosilicate concurrently.(1-3) Patiromer, sodium polystyrene sulfonate or sodium zirconium cyclosilicate are indicated for management of hyperkalemia. Consider discontinuing or holding potassium supplements in patients who develop hyperkalemia requiring treatment.

DISCUSSION: Patiromer, sodium polystyrene sulfonate and sodium zirconium cyclosilicate are indicated for hyperkalemia. Consider discontinuing or holding potassium supplements in patients receiving sodium polystyrene sulfonate or sodium zirconium cyclosilicate.

DEXTROSE 5%-ELECTROLYTE #48, EFFER-K, K-PHOS NO.2, K-PHOS ORIGINAL, KCL-D5W-0.2% NACL, KCL-D5W-0.225% NACL, KCL-D5W-0.45% NACL, KCL-D5W-0.9% NACL, KLOR-CON, KLOR-CON 10, KLOR-CON 8, KLOR-CON M10, KLOR-CON M15, KLOR-CON M20, KLOR-CON-EF, POKONZA, POTASSIUM ACETATE, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE IN D5LR, POTASSIUM CHLORIDE-0.45% NACL, POTASSIUM CHLORIDE-0.9% NACL, POTASSIUM CHLORIDE-DEXTROSE 5%, POTASSIUM CHLORIDE-WATER, POTASSIUM CL-LIDOCAINE-NS, POTASSIUM PHOSPHATE, POTASSIUM PHOSPHATE-0.9% NACL, POTASSIUM PHOSPHATES

There are 0 moderate interactions.

The following contraindication information is available for LOKELMA (sodium zirconium cyclosilicate):

Overview
Contraindicated
Severe
Moderate

Drug contraindication overview.

The manufacturer states that there are no known contraindications to the use of sodium zirconium cyclosilicate.

There are 1 contraindications. Absolute contraindication.

Contraindication List
Gastrointestinal obstruction

There are 1 severe contraindications. Adequate patient monitoring is recommended for safer drug use.

Severe List
Gastrointestinal hypomotility

There are 2 moderate contraindications. Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.

Moderate List
Chronic heart failure
Kidney disease with likely reduction in glomerular filtration rate (GFr)

The following adverse reaction information is available for LOKELMA (sodium zirconium cyclosilicate):

Overview
Severe
Less Severe

Adverse reaction overview.

Adverse effects reported in 4% or more of patients receiving sodium zirconium cyclosilicate in clinical studies include edema and hypokalemia.

There are 1 severe adverse reactions.

More Frequent	Less Frequent
None.	Hypokalemia

Rare/Very Rare
None.

There are 9 less severe adverse reactions.

More Frequent	Less Frequent
Constipation Edema Peripheral edema	Diarrhea Hypomagnesemia Muscle spasm

Rare/Very Rare
Gastroenteritis Hypocalcemia Vomiting

The following precautions are available for LOKELMA (sodium zirconium cyclosilicate):

Pediatric
Pregnant
Lactation
Geriatric

Safety and efficacy of sodium zirconium cyclosilicate have not been established in pediatric patients.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

Because sodium zirconium cyclosilicate is not absorbed systemically following oral administration, use of the drug during pregnancy is not expected to result in fetal exposure.

Breast-feeding is not expected to result in infant exposure to sodium zirconium cyclosilicate because the drug is not systemically absorbed following oral administration.

In clinical studies of sodium zirconium cyclosilicate, 58% of patients receiving the drug were 65 years of age or older and 25% were 75 years of age or older. No overall differences were observed between geriatric patients and younger adults.